JP2008519016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519016A5 JP2008519016A5 JP2007539613A JP2007539613A JP2008519016A5 JP 2008519016 A5 JP2008519016 A5 JP 2008519016A5 JP 2007539613 A JP2007539613 A JP 2007539613A JP 2007539613 A JP2007539613 A JP 2007539613A JP 2008519016 A5 JP2008519016 A5 JP 2008519016A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amisulpride
- dose
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 10
- 229960003036 amisulpride Drugs 0.000 claims 10
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 5
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 4
- 229960001736 buprenorphine Drugs 0.000 claims 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 229960001797 methadone Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960001534 risperidone Drugs 0.000 claims 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 206010012335 Dependence Diseases 0.000 claims 2
- 102000015554 Dopamine receptor Human genes 0.000 claims 2
- 108050004812 Dopamine receptor Proteins 0.000 claims 2
- 230000002973 anti-dopamine Effects 0.000 claims 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 2
- 229960003086 naltrexone Drugs 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 1
- NTJOBXMMWNYJFB-LBPRGKRZSA-N 4-amino-n-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-LBPRGKRZSA-N 0.000 claims 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 229960004503 metoclopramide Drugs 0.000 claims 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000938 nalorphine Drugs 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960004940 sulpiride Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0411810A FR2877573B1 (fr) | 2004-11-05 | 2004-11-05 | Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues |
| PCT/FR2005/002775 WO2006048560A2 (fr) | 2004-11-05 | 2005-11-07 | Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519016A JP2008519016A (ja) | 2008-06-05 |
| JP2008519016A5 true JP2008519016A5 (enExample) | 2008-12-18 |
Family
ID=34953312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539613A Pending JP2008519016A (ja) | 2004-11-05 | 2005-11-07 | 新規な医薬品組成物および様々な形の薬物嗜癖を制御するためのそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080090895A1 (enExample) |
| EP (1) | EP1814542A2 (enExample) |
| JP (1) | JP2008519016A (enExample) |
| CN (1) | CN101087603A (enExample) |
| AU (1) | AU2005300424A1 (enExample) |
| CA (1) | CA2586277A1 (enExample) |
| FR (1) | FR2877573B1 (enExample) |
| RU (1) | RU2007120707A (enExample) |
| WO (1) | WO2006048560A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1988883A1 (fr) * | 2006-02-17 | 2008-11-12 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4129655A (en) * | 1976-04-26 | 1978-12-12 | Ciba-Geigy Corporation | Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans |
| US4412999A (en) * | 1982-04-14 | 1983-11-01 | Merck & Co., Inc. | Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| WO1997035585A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Anesthetic method |
| MXPA04007936A (es) * | 2002-02-15 | 2004-11-26 | Upjohn Co | Compuestos de aril-sustituidos para el tratamiento de enfermedades. |
-
2004
- 2004-11-05 FR FR0411810A patent/FR2877573B1/fr not_active Expired - Fee Related
-
2005
- 2005-11-07 RU RU2007120707/15A patent/RU2007120707A/ru not_active Application Discontinuation
- 2005-11-07 CN CNA2005800448695A patent/CN101087603A/zh active Pending
- 2005-11-07 US US11/666,981 patent/US20080090895A1/en not_active Abandoned
- 2005-11-07 AU AU2005300424A patent/AU2005300424A1/en not_active Abandoned
- 2005-11-07 JP JP2007539613A patent/JP2008519016A/ja active Pending
- 2005-11-07 CA CA002586277A patent/CA2586277A1/fr not_active Abandoned
- 2005-11-07 WO PCT/FR2005/002775 patent/WO2006048560A2/fr not_active Ceased
- 2005-11-07 EP EP05816959A patent/EP1814542A2/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shipton | Tramadol—present and future | |
| JP2022523700A (ja) | 心理性、認知性、行動性、および／または気分性の障害を処置するための方法、ならびに５ｈｔ受容体アゴニストを含む組成物 | |
| US20180360760A1 (en) | Methods For Administering Weight Loss Medications | |
| US20090253728A1 (en) | Methods and Compositions for Treating Nociceptive Pain | |
| JP2005247859A5 (enExample) | ||
| US20100292216A1 (en) | Methods and Compositions for the Treatment of Psychiatric Conditions | |
| Power | An update on analgesics | |
| JP2010535801A5 (enExample) | ||
| JP2005512995A5 (enExample) | ||
| RU2000101024A (ru) | Опоидные анальгетики с контролируемым высвобождением активных веществ | |
| JP2002506047A (ja) | Ｎｍｄａレセプター拮抗薬及び麻酔性鎮痛薬を含む鎮痛組成物。 | |
| US12410195B2 (en) | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | |
| US20220056030A1 (en) | Organic compound | |
| JP2003520234A (ja) | 薬物中毒の治療方法 | |
| JP2008533142A (ja) | α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物 | |
| HRP20110049T2 (hr) | Opioidi za liječenje nemirnosti kod donjih ekstremiteta | |
| JP2009526833A5 (enExample) | ||
| JP2575569B2 (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| CN1889996A (zh) | 氟吡丁和曲马多的组合 | |
| JP2008519016A5 (enExample) | ||
| RU2004131213A (ru) | Лекарственные формы трамадола замедленного высвобождения | |
| WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time | |
| WO2007069925A2 (en) | Non-neurotoxic recreational drugs and a method of treating recreational drug abuse | |
| Bateman | Opioids | |
| WO2003088918A3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING α3β4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE |